Afrezza
Peptide
Evidence outlook
Approved: Type 2 Diabetes, Type 1 Diabetes
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00332488 NCT00332488 · Diabetes Mellitus, Type 2 The trial randomized 528 participants across three treatment groups and used an active comparator, but it was open-label rather than blinded and its primary endpoint was the surrogate measure HbA1c. The primary comparison was not met: HbA1c decreased by 0.70% with inhaled insulin plus metformin versus 0.78% with metformin plus secretagogue (p=0.420). Registry: NCT00332488 | 3 | Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue (Baseline to Week 12) 2008-03 | Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue (Baseline to Week 12): TI Inhalation Powder + Metformin -0.7 Percentage of total hemoglobin (95% CI -0.84 to -0.56) vs Metformin & Secretagogues -0.78 Percentage of total hemoglobin (95% CI -0.92 to -0.64) | Partial signal | link ↗ |
View 3 more trials
INHALE-1 NCT04974528 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 The study randomized 230 children and adolescents to mealtime Afrezza or to rapid-acting insulin injections, each with basal insulin; treatment was open-label rather than blinded. The primary endpoint was non-inferiority on HbA1c change at week 26, with a margin of 0.4 percentage points. The FDA label gives a difference of 0.18 percentage points (95% CI -0.07 to 0.44) and states that the primary endpoint of non-inferiority was not met. The figures are from the FDA label. Registry: NCT04974528 | 3 | Change in HbA1c from baseline to week 26 (non-inferiority vs rapid-acting insulin analog, margin 0.4%) 2024-10-03 | HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. | Partial signal | link ↗ |
NCT00539890 NCT00539890 · Diabetes Type 2 This 24-week trial randomly assigned people with type 2 diabetes to Technosphere inhaled insulin or to insulin aspart, each added to insulin glargine. It was open-label, so treatment assignment was known throughout. The prespecified primary analysis was equivalence on HbA1c change in the intention-to-treat population: the difference was 0.26 percentage points and the predefined equivalence margin was not met. A per-protocol non-inferiority analysis in the full text is supportive only and does not change the primary result. Registry: NCT00539890 | 3 | Change in HbA1c from baseline to week 24 (equivalence analysis, Technosphere insulin vs insulin aspart, each added to basal insulin) | HbA1c change at 24 weeks (ITT, 150 Technosphere insulin vs 154 insulin aspart, each with glargine): 8.9% to 7.9% vs 9.0% to 7.7%; treatment difference 0.26 percentage points; the predefined equivalence margin was not met. | Partial signal | link ↗ |
NCT01451398 NCT01451398 · Type 2 Diabetes This was a randomized, double-blind, placebo-controlled trial, and inhaled insulin significantly lowered HbA1c versus placebo at week 24 (difference -0.40%, p<0.0001). The evidence is rated below the top level because neither a sample size calculation nor a planned enrolment was found in the sources checked. Registry: NCT01451398 | 3 | Change From Baseline to Week 24 in HbA1c 2013-06 | Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Competitive landscape
Other Insulin drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Afrezza: this drug | Approved | Peptide | Insulin | Partial signal | NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis). | |
| Insulin Aspart (NovoLog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Aspart (Fiasp) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Detemir (Levemir) | ApprovedUS marketing discontinued | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Lantus) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Basaglar) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Toujeo) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Human | Approved | — | Insulin | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Lyumjev) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin NPH (Humulin N) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pramlintide (Symlin) | ApprovedUS marketing discontinued | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cadisegliatin | Phase 3 | Small molecule | Glucokinase | not yet graded | No reviewed efficacy summary in this indication | |
| Sotagliflozin (Inpefa) | Phase 3 | Small molecule | SGLT1/2 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Zimislecel | Phase 3 | Cell therapy | Pancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacement | not yet graded | No reviewed efficacy summary in this indication | |
| Icovamenib | Phase 2 | Small molecule | Menin | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Afrezza to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
March 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent